<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22837" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Herpes Simplex Neonatorum</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Boyd</surname>
            <given-names>Roland L.</given-names>
          </name>
          <aff>Rush Health Systems</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ward</surname>
            <given-names>Rebecca</given-names>
          </name>
          <aff>University of Florida</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kasman</surname>
            <given-names>Laura M.</given-names>
          </name>
          <aff>Medical University of South Carolina</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Roland Boyd declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rebecca Ward declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Laura Kasman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22837.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Herpes simplex virus (HSV) infections in the neonatal period continue to be troublesome for practitioners. In the 1970s, the drug vidarabine was introduced, but it was extremely toxic to the neonate, and there was little improvement in outcomes. The development of acyclovir in the 1980s led to significant improvements in the survival of infected infants. Mortality of infants with the disseminated disease has decreased from 85 percent to 29 percent, and patients with central nervous system (CNS) disease has decreased from 50 percent to roughly 4 percent in industrialized countries. This activity reviews the evaluation and management of neonatal herpes and stresses the role of the interprofessional team in the care of affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of neonatal herpes.</p></list-item><list-item><p>Describe the evaluation of neonatal herpes.</p></list-item><list-item><p>Outline the treatment options available for neonatal herpes.</p></list-item><list-item><p>Explain interprofessional team strategies for improving care coordination to advance outcomes for patients with neonatal herpes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22837&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22837">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22837.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>With the development of acyclovir in the 1980s, there was a vast improvement in the overall survival of these infected infants.&#x000a0;At present, the mortality of infants with disseminated disease has decreased from 85% to 29%, and patients with central nervous system (CNS) disease has decreased from 50% to roughly 4% in industrialized countries. Unfortunately, it&#x000a0;remains elevated in developing nations.</p>
      </sec>
      <sec id="article-22837.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>There are 8 herpes viruses,&#x000a0; <italic toggle="yes">Herpes simplex</italic> virus type 1 (HSV-1), <italic toggle="yes">Herpes simplex</italic> virus type 2 (HSV-2), <italic toggle="yes">Cytomegalovirus</italic> (CMV), <italic toggle="yes">Epstein-Barr</italic> virus (EBV),&#x000a0;&#x000a0;<italic toggle="yes">Varicella-zoster,</italic>
<italic toggle="yes">Human herpesvirus</italic> 6 (HHV-6), <italic toggle="yes">Human herpesvirus</italic> 7 (HHV-7), and <italic toggle="yes">human herpesvirus</italic> 8 (HHV-8). Herpes simplex neonatorum is the transmission of either HSV-1 or HSV-2 from the mother to child during gestation via the placenta, during delivery via vaginal secretions, or perinatally via direct contact with active lesions.</p>
      </sec>
      <sec id="article-22837.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence of HSV-1 and HSV-2 has changed over the past few decades. Currently, over one-third of the world&#x02019;s population has recurrent HSV infection. By age 5, 35% of black children are infected by HSV-1, and 18% of white children are infected. Genital herpes is predominately caused by HSV-2 in the United States; however, in Japan, the predominant cause of genital herpes is caused by HSV-1.<xref ref-type="bibr" rid="article-22837.r1">[1]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-22837.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The HSV is a double-stranded DNA virus that is large and has a surrounding lipid envelope.&#x000a0;The DNA in HSV-1 and HSV-2 have many similarities, thus causing much cross-reactivity in antibody production.&#x000a0;The virus enters the body through epithelial cells or mucous membranes.&#x000a0;When it has replicated within the nucleus of the cells, it travels down the axon to the neurons, where it can establish a latent infection.</p>
      </sec>
      <sec id="article-22837.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The cutaneous findings are scarring, active lesions, hypo, and hyperpigmentation of the skin, cutis aplasia, and macular rashes.&#x000a0;In the eyes, one may see microphthalmia, retinal dysplasia, optic atrophy, and or chorioretinitis.&#x000a0;Neurologically one can see microcephaly, encephalomalacia, hydranencephaly, and intracranial calcifications.&#x000a0;Infants with disseminated disease often present in the first three weeks of life with symptoms of sepsis.&#x000a0;Multiple organ systems can be affected by this illness, causing&#x000a0;jaundice, abnormal liver function, hypoglycemia, hypotension, coagulopathy, pneumonia, and even respiratory failure.&#x000a0;Encephalitis is present 75% of the time in disseminated disease, thus causing seizures.&#x000a0;&#x000a0;Rarely do these infants present with vesicular lesions. Death usually results from shock, progressive liver failure, severe coagulopathy, respiratory failure, and progressive neurological deterioration. These infants usually present around the second or third week of life.&#x000a0;They may initially have a fever, poor feeding, or present with a sudden episode of seizures or apnea.&#x000a0;Between 60% and 70% of babies classified as having CNS disease have associated skin lesions at some point in the course of their illness.&#x000a0;Skin, eye, and mouth disease also presents in the second to the third week of life.&#x000a0;Typical&#x000a0;vesicular lesions on an erythematous base are the presenting sign.&#x000a0;Rarely are&#x000a0;lesions present in the mouth.&#x000a0;Conjunctivitis is often present and, left untreated, may develop into herpetic keratitis and possibly even corneal blindness.&#x000a0;SEM has low mortality but reoccurs in 90% of patients.<xref ref-type="bibr" rid="article-22837.r2">[2]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-22837.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Viral culture is the &#x0201c;gold standard&#x0201d; for verification of HSV infection.&#x000a0;Cultures should be obtained from lesions that are&#x000a0;scraped or from the mucous membranes and transported to a viral lab on ice. The virus can also be cultured from cerebrospinal fluid (CSF), blood, urine, stool, rectum, oropharynx, and conjunctivae.&#x000a0;After the virus is inoculated into the cell culture system and grows, it may then be further identified as HSV-1 or HSV-2.&#x000a0;The greatest viral yield continues to be isolated from intact skin lesions, which are scraped and from the conjunctivae.&#x000a0;Polymerase chain&#x000a0;reaction&#x000a0;(PCR) allows for the rapid diagnosis of HSV in the clinical setting.&#x000a0;PCR is very accurate, with a reported sensitivity of 80% and an overall specificity&#x000a0;of 71%.&#x000a0; A Tzank smear looks for multinucleated giant cells in any lesion that may be suspicious of HSV. Other laboratory studies may be abnormal but not diagnostic, yet may be suggestive of HSV infection, including leukopenia, thrombocytopenia, elevated liver enzymes, hypoglycemia, and elevated protein in the CSF.<xref ref-type="bibr" rid="article-22837.r3">[3]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-22837.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>They may require intubation and placement on ventilators and or can have severe hypotension requiring volume boluses and pressors&#x000a0;for blood pressure support. Once they are respiratory,&#x000a0;neurologically, and hemodynamically stable, one may start appropriate intravenous&#x000a0;antiviral therapy. Congenital HSV-infected infants still require therapy. Intravenous (IV) acyclovir for 21 days is thought to prevent further replication of the virus and to decrease the number of future outbreaks. CT or MRI of the&#x000a0;brain should be performed to evaluate the brain for any signs of abnormal&#x000a0;findings.&#x000a0;A pediatric ophthalmologist should evaluate for signs of keratitis or optic atrophy.&#x000a0;Infants with disseminated or CNS disease should be treated with intravenous&#x000a0;(IV) acyclovir 20 mg/kg/dose every 8 hours for a total of 21 days.&#x000a0;If CSF is unable to be obtained for culture or PCR, one should err on the side of caution and treat for a full 21 days.&#x000a0; Also, at the end of the 21-day treatment, a blood HSV PCR should be sent to ensure the virus has been eliminated.&#x000a0;Morbidity from disseminated (SEM) disease has dramatically improved with the use of acyclovir.&#x000a0; Duration is limited to a 14-day treatment, and a blood HSV PCR should be obtained, and if the results are positive, the infant should be treated for another seven days or until a negative result is obtained.&#x000a0;In premature infants with HSV disease requiring acyclovir, the dosing interval may need to be increased secondary to their decreased creatinine clearance.&#x000a0;All patients receiving acyclovir should be followed twice weekly for signs of a low absolute&#x000a0;neutrophil count, as this occurs in approximately one-fifth of all patients.<xref ref-type="bibr" rid="article-22837.r4">[4]</xref><xref ref-type="bibr" rid="article-22837.r5">[5]</xref><xref ref-type="bibr" rid="article-22837.r6">[6]</xref>&#x000a0;</p>
        <p>After IV treatment, suppressive therapy with oral acyclovir 300 mg/m<sup>2</sup>&#x000a0;per dose three times per day for six months.<xref ref-type="bibr" rid="article-22837.r5">[5]</xref></p>
      </sec>
      <sec id="article-22837.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Neonatal sepsis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pediatric aphthous ulcers</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pediatric chickenpox</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pediatric cytomegalovirus infection</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pediatric enteroviral infections</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pediatric erythema toxicum</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pediatric sepsis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Zoster</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22837.s10" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>All infants born to mothers with a history of genital HSV have surface and mucosal cultures performed at 24 hours of life and also a blood HSV PCR.&#x000a0;If these studies are negative, and the infant is asymptomatic, the infant may be discharged with the mother. Infants born to mothers with active genital lesions and having a prior history of HSV, whether it be C-section or vaginal delivery, are to be screened with mucosal &#x000a0;HSV cultures and blood for HSV PCR.</p>
      </sec>
      <sec id="article-22837.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>An interprofessional team can improve outcomes for infants with disseminated HSV. The involvement of primary care providers, neonatologists, infectious disease, specialty-trained nurses, and pharmacists is recommended. Prompt recognition and treatment are imperative. Nurses administer treatment, monitor patients, and keep the team apprised of patient status. Infectious disease or pediatric pharmacists review medications and check doses. [Level 5]</p>
      </sec>
      <sec id="article-22837.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22837&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22837">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/herpes-simplex-neonatorum-neonatal-herpes-simplex-virus-infection/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22837">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22837/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22837">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22837.s13">
        <title>References</title>
        <ref id="article-22837.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flagg</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Weinstock</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Incidence of neonatal herpes simplex virus infections in the United States, 2006.</article-title>
            <source>Pediatrics</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>127</volume>
            <issue>1</issue>
            <fpage>e1</fpage>
            <page-range>e1-8</page-range>
            <pub-id pub-id-type="pmid">21149432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22837.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curfman</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Glissmeyer</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Korgenski</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Blaschke</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Byington</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Initial Presentation of Neonatal Herpes Simplex Virus Infection.</article-title>
            <source>J Pediatr</source>
            <year>2016</year>
            <month>May</month>
            <volume>172</volume>
            <fpage>121</fpage>
            <page-range>121-126.e1</page-range>
            <pub-id pub-id-type="pmid">26960921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22837.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Bird's Eye View of a Neonatologist: Clinical Approach to Emergency Neonatal Infection.</article-title>
            <source>Pediatr Neonatol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>57</volume>
            <issue>3</issue>
            <fpage>167</fpage>
            <page-range>167-73</page-range>
            <pub-id pub-id-type="pmid">26701838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22837.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kimberlin</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Baley</surname>
                <given-names>J</given-names>
              </name>
              <collab>Committee on infectious diseases</collab>
              <collab>Committee on fetus and newborn</collab>
            </person-group>
            <article-title>Guidance on management of asymptomatic neonates born to women with active genital herpes lesions.</article-title>
            <source>Pediatrics</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>131</volume>
            <issue>2</issue>
            <fpage>e635</fpage>
            <page-range>e635-46</page-range>
            <pub-id pub-id-type="pmid">23359576</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22837.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kimberlin</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Whitley</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Wan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Storch</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Shelton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dennehy</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Leach</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rathore</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abughali</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Frenkel</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Van Dyke</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Guzman-Cottrill</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jester</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lakeman</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Cloud</surname>
                <given-names>GA</given-names>
              </name>
              <collab>National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group</collab>
            </person-group>
            <article-title>Oral acyclovir suppression and neurodevelopment after neonatal herpes.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>Oct</month>
            <day>06</day>
            <volume>365</volume>
            <issue>14</issue>
            <fpage>1284</fpage>
            <page-range>1284-92</page-range>
            <pub-id pub-id-type="pmid">21991950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22837.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>James</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kimberlin</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Neonatal Herpes Simplex Virus Infection.</article-title>
            <source>Infect Dis Clin North Am</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>391</fpage>
            <page-range>391-400</page-range>
            <pub-id pub-id-type="pmid">26154662</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
